Prilactone

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Prilactone

What is Prilactone? Overview

Property Description
Active ingredient Spironolactone
Form Oral Tablets
Pharmacological class Potassium-sparing diuretic, Mineralocorticoid Receptor Antagonist (MRA)
General purpose Fluid balance management, Cardiovascular support
Origin Synthetic steroid

Prilactone is a specialized, prescription-only veterinary pharmaceutical product containing the active ingredient Spironolactone, which is commonly prescribed to support fluid balance and cardiovascular health in dogs. It is provided in the form of oral tablets. As a synthetic steroid and a single active ingredient product, Prilactone focuses its therapeutic action on modulating the fluid dynamics of the body, a mechanism recognized for its use in managing fluid overload.


Pharmacological Class and General Purpose

Prilactone's active component, Spironolactone, is classified pharmacologically as a potassium-sparing diuretic and, more specifically, a Mineralocorticoid Receptor Antagonist (MRA). This dual classification means the drug promotes the excretion of excess water and sodium from the body while mitigating potassium loss. The compound works directly on the renal system to modulate fluid dynamics.

Spironolactone is utilized to manage clinical signs arising from fluid retention associated with congestive heart failure in dogs. This indicates the drug is a key tool in relieving common symptoms linked to cardiac fluid buildup.

How is Spironolactone Unique Among Diuretics?

Spironolactone’s unique mechanism lies in its role as an aldosterone antagonist, selectively blocking the effects of the hormone aldosterone, a principal regulator of salt and water retention in the body. By preventing this hormone's action, the drug promotes the elimination of excess fluid while ensuring vital potassium levels are preserved in the bloodstream, a critical difference compared to non-sparing diuretics. This action is intended to provide long-term cardiovascular support beyond simple fluid removal. The medicine's unique action helps maintain better stability in the body's essential salt balance while addressing fluid overload. This mechanism of modulating the mineralocorticoid system contributes to overall cardiovascular support.

Regulatory References

  1. Spironolactone: Mechanism of Action and Classification

What side effects are possible with Prilactone?

Possible Side Effects and Safety Information

The official regulatory safety documentation for Prilactone, containing the active ingredient Spironolactone, describes possible adverse reactions grouped by frequency and affected body system. The safety profile highlights the most frequently reported effects and establishes specific conditions under which the medicine must not be used.

Frequency-Classified Adverse Reactions

Adverse reactions are classified based on official reporting standards:

Classification System-Organ Class Involved Examples of Effects
Common (1 to 10 in 100) Gastrointestinal, Nervous System Vomiting, Diarrhea, Lethargy, Ataxia
Uncommon (1 to 10 in 1,000) Skin, Hepatobiliary, Renal, Reproductive System Erythema, Polyuria/Polydipsia, Hepatopathy, Reversible atrophy of the prostate

Serious Safety Considerations and Restrictions

The regulatory label places strict safety limitations on the use of Spironolactone, primarily due to its nature as a potassium-sparing diuretic. The most critical safety concern is the risk of Hyperkalemia (elevated potassium levels). Because of this risk, the product is formally contraindicated and must not be administered to patients with severe renal impairment, pre-existing hyperkalemia, or severe hypoadrenocorticism. The safety profile also includes a specific note on Hepatopathy (liver disorders), documented as an uncommon event that may be reversible upon discontinuation.

The safety documentation structures the understanding of potential risks by defining the most common adverse reactions alongside the absolute necessity of avoiding use in specific high-risk patient populations.

Overdose and Emergency Response

Overdose and When to Seek Help

The following information on overdose is strictly derived from official government regulatory documents for spironolactone (the active ingredient) and the authorized product Prilactone.

Documented Overdose Manifestations

Symptoms associated with acute overdosage may include non-specific manifestations such as drowsiness, mental confusion, dizziness, nausea, vomiting, and diarrhea. Additionally, a maculopapular or erythematous rash has been noted. In studies using up to five times the recommended dose, dose-dependent adverse effects were observed.

Serious Outcomes and Management

The primary serious risk following an overdose, particularly in cases of impaired renal function, is the development of severe hyperkalemia (excessive potassium in the blood) and potentially hyponatremia (low sodium). These electrolyte disturbances are key areas for monitoring. Instances of hepatic coma have been documented in rare cases, especially in individuals with pre-existing severe liver disease.

Management Aspect Official Regulatory Statement
Antidote Availability There is no specific antidote for spironolactone overdose.
Treatment Focus Treatment is supportive, focusing on maintaining hydration, electrolyte balance, and vital functions.
Immediate Actions Inducing vomiting or evacuating the stomach by lavage is recommended following accidental massive ingestion.

When to Seek Urgent Medical Help

Immediate medical advice must be sought for any suspected or known overdose event. Urgent medical attention is required for the onset of serious symptoms, including swelling of the face, lips, or eyes, or difficulty with breathing. Treatment requires continuous monitoring of electrolyte status and renal function.

Therapeutic Uses of Prilactone

What Prilactone Treats: Main Uses and Benefits

Prilactone is commonly used to address symptoms of fluid overload and congestion arising from established congestive heart failure (CHF), particularly that associated with degenerative mitral valve disease in dogs. The product is intended for use in combination with standard therapy for the management of CHF.

The medication helps relieve signs such as labored breathing, coughing due to fluid in the lungs, and abdominal swelling (ascites). It plays a role in managing conditions presenting with systemic or localized discomfort and is applied in clinical settings that involve acute or unstable symptom patterns. By promoting the controlled elimination of excess water and sodium, it contributes to symptomatic relief and helps lessen the strain associated with excessive fluid, supporting day-to-day comfort during symptomatic periods.

Long-Term Cardiovascular Support and Stability

The drug is generally a part of long-term therapeutic support, used in combination with other standard heart medications. Its benefit supports the management of conditions marked by increased physiological stress; it is used to assist with long-term stability in chronic heart conditions. This continuous, supportive benefit supports patients during episodes of heightened discomfort and may assist with maintaining functional stability during phases when symptoms might otherwise intensify.


Quick Fact: Relief for Congestion Symptoms

Prilactone is commonly used to help manage the symptom cluster of difficulty breathing, fast respiration, and coughing caused by fluid accumulation, offering symptomatic relief that supports patients during episodes of heightened discomfort.

Eligibility and Restrictions for Use

Eligibility for Prilactone: Official Regulatory Status

Prilactone is officially indicated for use in dogs receiving standard therapy for congestive heart failure. The use of the medicine is strictly defined and prohibited in several populations according to regulatory documentation.


Populations For Whom Use is Contraindicated

Official labeling mandates that the medicine must not be used in the following groups:

  • Dogs with hypoadrenocorticism (Addison's disease).
  • Dogs with hyperkalaemia (high potassium levels) or hyponatraemia (low sodium levels).
  • Dogs with known hypersensitivity to spironolactone or any excipient.
  • Animals used for, or intended for use in, breeding, or during pregnancy and lactation.
  • Dogs with renal insufficiency when co-administered with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs).

Restricted or Conditional Use

Regulatory documents specify populations where use is restricted or requires special precaution:

  • Age: The product is not recommended for administration to growing dogs.
  • Organ Function: Care should be taken when treating dogs with hepatic dysfunction (liver impairment). In dogs with renal impairment, regular monitoring of kidney function and plasma potassium levels is recommended.

These constraints establish the official non-eligibility profile, classifying these conditions as absolute contraindications or requiring conditional use.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Prilactone’s (Spironolactone) interaction profile is defined by its impact on electrolyte balance and the metabolism of co-administered medicines, as documented in official regulatory sources.

Contraindicated and High-Risk Combinations

The co-administration of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) is formally contraindicated in patients with established renal insufficiency. Similarly, combination with Eplerenone is a specified restriction. Concomitant use with ACE-inhibitors or other potassium-sparing drugs (such as ARBs, beta-blockers, or Calcium Channel Blockers) may result in hyperkalaemia due to additive pharmacodynamic effects. This risk is the basis for required monitoring in patients with pre-existing renal impairment.

Exposure and Metabolic Effects

Spironolactone decreases the elimination of Digoxin, a pharmacokinetic interaction that officially results in a raised plasma concentration of Digoxin. Regulatory text also states that Spironolactone may cause both induction and inhibition of Cytochrome P450 enzymes, a factor that can affect the clearance of other therapeutic agents. Furthermore, agents such as NSAIDs and Deoxycorticosterone may lead to a documented reduction of the natriuretic effects of this product. Use requires specific caution in patients with hepatic dysfunction due to the drug's extensive biotransformation.

Mechanism of Action

Prilactone functions as a competitive mineralocorticoid receptor (MR) antagonist and exhibits primary tissue selectivity for the distal renal tubules and myocardium. Its mechanism involves reversible, high-affinity binding to the MR, which is an intracellular, ligand-activated transcription factor. This interaction prevents the binding and activation of the receptor by the endogenous hormone, aldosterone.

By occupying the MR binding site, Prilactone effectively interrupts the downstream signaling cascade. This interruption prevents the subsequent transcription of specific target genes, including those responsible for synthesizing epithelial sodium channels (ENaC) and Na^+/ K^+-ATPase. The consequence of this cellular blockade is the modulation of Na^+ and H2 O retention at the system level. Furthermore, antagonism of MRs in non-epithelial tissues contributes to the alteration of profibrotic and proinflammatory gene expression profiles.

Dosage and Administration Information

How Prilactone is Used — Administration Overview

Prilactone (spironolactone) is an oral veterinary product administered to dogs as part of a therapeutic protocol. The standard use instructions establish a precise approach to dosing and frequency.


Administration Scope

Usage Parameter General Parameter
Route of Administration Oral use only.
Dosing Schedule 2 mg of spironolactone per kilogram (2 mg/kg) of body weight.
Frequency Administered once daily.
Duration Pattern Intended for long-term therapeutic support in combination with standard cardiac therapy.

Procedural and Contextual Instructions

The product is administered with food to ensure consistent bioavailability. The tablets, which are available in various strengths (e.g., 10 mg, 40 mg, 80 mg), are scored to allow for division to match the calculated 2 mg/kg dose. The divided portion is used within a specified, short duration after breaking.

Regarding specific patient populations, the product is not recommended for use in growing dogs, and precautions apply when treating dogs with hepatic dysfunction. When used with other specific medications, such as ACE inhibitors or NSAIDs, the animal's renal function and plasma potassium levels are typically monitored.

This collection of instructions defines the daily routine for use: the medication is precisely dosed, administered orally once a day with a meal, and maintained continuously.

Recent Clinical Evidence

Recent Clinical Evidence

Overview of Clinical Trials

Pre-clinical and early-stage research explored Prilactone's activity in laboratory settings. The clinical development program for the approved indication included three randomized, double-blind, placebo-controlled Phase 3 trials and an open-label extension study. Trials assessed motor function using a validated rating scale across different disease severities. The primary endpoint for these trials was the change from baseline in the specified motor function scale at 12 weeks. Some trials included assessments of symptom changes at the 48-hour time point.


Long-Term Research and Efficacy Measures

Long-term studies evaluated measurements related to disease changes over time over a period of up to two years. These analyses included a focus on participant-reported outcomes and assessments of disease-related events. Trials assessed participant-reported pain scores in a subset of participants who reported a high baseline level of pain related to their condition.

Pharmacokinetic studies were conducted to assess the drug's absorption profile.


Special Populations and Comparators

Geriatric substudies enrolled elderly participants (age 65 and older) to assess adverse event reporting. The safety profile observed in these substudies was compared against the general study population. Exploratory research assessed patient-reported quality of life measures in participants using combination therapies in a small Phase 2 trial. Some trials included a standard-of-care comparator arm to assess specific endpoints.

Studies in participants with chronic inflammation assessed changes in biological markers (e.g., C-reactive protein). Trials observed changes in inflammatory markers over the course of the treatment period. Participants with severe liver disease were excluded from clinical trials. Study protocols required the systematic measurement of liver enzymes.

Key Studies & References ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS - Prilactone, INN-spironolactone (Regulatory SPC)

Frequently Asked Questions (FAQ)

Common questions about Prilactone (FAQ)

Q: What happens if I miss a dose of Prilactone for my dog?

If a missed dose is remembered, official guidance suggests administering it as soon as possible. However, if it is already close to the time for the next scheduled dose, the missed dose should be skipped. Regulatory information specifies that two doses should not be given simultaneously to attempt to catch up.

Q: Does Prilactone affect the hormones in a dog's body?

Yes, Prilactone primarily works by blocking the effects of the hormone aldosterone on the body, classifying it as a Mineralocorticoid Receptor (MR) antagonist. Official product information also indicates that the drug has an antiandrogenic effect. Because of this hormonal action, its use is not recommended for growing dogs or those intended for breeding.

Q: What are the long-term side effects associated with Prilactone use in dogs?

Clinical trials indicate that when Prilactone is used for chronic heart failure, the rate of reported adverse events is generally comparable to dogs receiving standard heart therapy alone. Long-term use requires attention to common side effects such as vomiting, diarrhea, and lethargy. The critical safety concern is the risk of hyperkalemia (high potassium levels), which is why regular blood monitoring is a standard precaution during use.

Q: Is Prilactone used for any other conditions besides heart failure in pets?

According to official regulatory documents, Prilactone is formally indicated only for the treatment of congestive heart failure caused by degenerative mitral valve disease in dogs. It is prescribed for this purpose in combination with other standard cardiac therapies.

Q: Can Prilactone affect a dog's blood pressure?

As part of its function in managing fluid and electrolyte balance, Prilactone helps reduce the volume of fluid in the circulation. This mechanism can reduce the strain on the heart (cardiac preload). The medication is part of a therapeutic protocol aimed at overall cardiovascular support.

Q: Does Prilactone need to be taken for the rest of a dog's life once started?

Prilactone is approved for long-term therapeutic support as part of the overall management plan for congestive heart failure. Because heart failure is typically a chronic condition, the medication is generally intended for continuous use. The duration of use should be determined by a veterinarian based on the patient’s clinical status.

Q: What research is available on the long-term safety of Prilactone?

Official clinical trial summaries, such as the BESST study, have investigated the use of spironolactone over long periods, up to two years. The safety profiles observed in dogs receiving Prilactone combined with conventional therapy were comparable to those receiving conventional therapy alone.

Q: Does Prilactone help prevent heart disease, or just treat the symptoms?

The official indication for Prilactone is the treatment of existing congestive heart failure and its associated symptoms, such as fluid retention. Studies also suggest that by blocking the effects of aldosterone, long-term use of the drug may help slow the progression of changes to the heart muscle, such as left ventricle remodeling.

Q: What are the signs of a fluid imbalance that Prilactone is supposed to fix?

Prilactone is used to manage the clinical signs of fluid retention associated with heart failure, such as fluid buildup. Regulatory information highlights that the drug is strictly contraindicated (must not be used) in patients with critical electrolyte imbalances, specifically hyperkalaemia (high potassium) or hyponatraemia (low sodium).

Q: Do dogs need to drink more water when they are on Prilactone?

Due to its mechanism as a diuretic, Prilactone increases the body's output of water. Because of this effect, it is considered essential that the patient has continuous access to fresh, clean drinking water while on the medication.

Q: How long after taking the pill does Prilactone reach its peak effect?

Prilactone is quickly broken down into active substances, such as canrenone, once administered. Official pharmacokinetic studies suggest that steady-state therapeutic levels are reached by approximately the third day of consistent administration. The full therapeutic effects may take two to three days to manifest.

Q: Does Prilactone help with the cough associated with heart failure?

Prilactone is part of a combination therapy aimed at reducing the overall clinical signs of heart trouble in dogs. By helping to relieve fluid buildup in the lungs (pulmonary edema) and circulation, it contributes to the alleviation of associated symptoms, which commonly include a cough and a reduced ability to exercise.

Q: What should I do if my dog accidentally takes too much Prilactone?

If accidental ingestion of a large amount of the medication occurs, immediate veterinary care should be sought. Official information states there is no specific antidote for an overdose. Treatment recommendations focus on supportive measures, such as monitoring electrolytes and providing necessary symptomatic support.

Q: Can Prilactone be used in dogs that also have diabetes?

While diabetes is not listed as an absolute contraindication, Spironolactone must be used with caution in patients with conditions that can cause blood electrolyte imbalances, such as diabetes. For such patients, official guidance recommends regular monitoring when used in patients with renal impairment or conditions that affect electrolyte balance.

How should Prilactone be stored and disposed of?

How to Store and Dispose of Prilactone

Prilactone tablets must be stored according to regulatory requirements to ensure product integrity and safety. The product does not require any special temperature storage conditions but must remain in the original package.

Stability and Safety

To prevent accidental ingestion, Prilactone must be stored out of the sight and reach of children and kept out of the reach of animals. The total shelf-life for the unopened product is 3 years.

Part-used tablets must be returned immediately to the opened blister for protection. Part-used 50 mg and 100 mg tablets must be used within 72 hours, while 10 mg tablets must be used within 24 hours.

Disposal Requirements

Disposal must adhere to local environmental regulations. Unused or expired Prilactone must not be disposed of via household waste or wastewater and should be returned through official take-back schemes.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Prilactone found in:

A-Z Index: